Biological activity of pyrazole derivatives as promising molecular scaffold for potential antiviral agents
Persistent viral infections are an important cause of human morbidity and mortality worldwide. The creation of new drugs for the prevention and treatment of viral diseases is one of the most urgent problems of modern medical practice. Pyrazole and thiadiazine derivatives demonstrate remarkable biological activities and have already been used for therapeutic purposes. Given the diverse activities associated with these moieties, their combination in heterocycles holds great potential for the development of antiviral drugs. In this article, we present the pharmacological and pharmacokinetic parameters of new pyrazole derivates. Pharmacokinetic parameters of compounds were evaluated in silico using the ADMETlab 2.0 online resource. The in vitro antioxidant activity of the compounds was measured by the free radical scavenging capacity according to the DPPH test. Cytotoxicity and antiviral efficacy were determined using a tetrazolium-based colorimetric and yield reduction assays, respectively. All studied compounds are characterized by optimal values of physicochemical parameters, meet the Lipinski rules and have pharmacokinetic profile corresponding to a potential drug. The composition of the halogenomethyl group in pyrazolotiadiazine has a significant effect on biological properties of the compound. Thus, 3-[bromodifluoromethyl]-5,7-dimethyl-4,7-dihydropyrazolo[4,3-e][1,2,4]thiadiazine-1,1-dioxide showed the highest free radical scavenging activity (47-55%). Pyrazole derivatives have more growth inhibitory effect on immortalized marmoset lymphoblastoid B-cells, then on normal monkey kidney epithelial cells (CC 50 value was in range 420 – 1095 and 1875 – ≥5000 μg/mL, respectively). Pyrazolotiadiazines showed pronounced ability to inhibit the reproduction of human adenovirus type 2. Inclusion of a dichloromethyl substituent in 5,7-dimethyl-4,7-dihydropyrazolo[4,3-e][1,2,4]thiadiazine1,1-dioxide significantly increased its anti-adenovirus activity. At the highest studied concentrations compound inhibited the development of the cytopathogenic effect by 79-86% and completely blocked the synthesis of infectious full-fledged virus progeny. Therefore, we provide a novel pyrazolothiadiazine as a promising scaffold for the design of potential antiadenoviral and antioxidant agents.
Authors
- Svіtlana Zahorodnia (ORCID: https://orcid.org/0000-0002-0892-772X)
- Liubov Biliavska (ORCID: https://orcid.org/0000-0003-3163-2492)
- Oleksandr Shalimov (ORCID: https://orcid.org/0000-0002-1538-3206)
- Andrii A. Zaremba (ORCID: https://orcid.org/0000-0003-0186-1235)
- Olga Povnitsa (ORCID: https://orcid.org/0000-0003-0349-7174)
- Polina Yu. Zaremba (ORCID: https://orcid.org/0000-0001-7253-0404)
- Nadiia Osypchuk
Institutions
- National Academy of Sciences of Ukraine (UA)
- Danylo Zabolotny Institute of Microbiology and Virology (UA)
- Institute of Organic Chemistry (UA)
- Bogomolets National Medical University (UA)
Publication Details
- Journal
- Heliyon
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1016/j.heliyon.2026.e45757
- Primary Topic
- Heterocyclic Compound Synthesis and Bioactivity
- Type
- article
- Field-Weighted Citation Impact
- 0.00